SENSUS HEALTHCARE, INC. (NASDAQ:SRTS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
The Annual Meeting of Stockholders (the Annual Meeting) of Sensus
Healthcare, Inc. (the Company) was held on June 5, 2017. At the
Annual Meeting, the Stockholders approved the Sensus Healthcare,
Inc. 2017 Incentive Plan (Plan). The Plan was previously approved
by the Board of Directors of the Company. A summary of the
material terms of the Plan is included under the heading Proposal
No. 2 Approval of the 2017 Equity Incentive Plan of the Companys
2017 Proxy Statement, which was filed with the Securities and
Exchange Commission on April 21, 2017, and is incorporated by
reference herein. The Plan summary is qualified in its entirety
by reference to the text of the Plan, which is filed as an
exhibit to this Form 8-K and incorporated by reference herein.
Submission of Matters to a Vote of Security
Proxies for the Annual Meeting held on June 5, 2017 were
solicited to Regulation 14A under the Securities Exchange Act of
1934, and there was no solicitation in opposition to managements
solicitation. The following summarizes all matters voted on at
the Annual Meeting.
John Heinrich and Anthony Petrelli were each elected as a
Stockholders approved the Sensus Healthcare, Inc. 2017
Incentive Plan. The number of votes cast were as follows:
Stockholders ratified the appointment of Marcum LLP as the
Companys independent registered public accountant. The number
of votes cast were as follows:
|Item 9.01||Financial Statements and Exhibits|
|10.1||Sensus Healthcare, Inc. 2017 Incentive Plan|
About SENSUS HEALTHCARE, INC. (NASDAQ:SRTS)
Sensus Healthcare, Inc., formerly Sensus Healthcare, LLC, is a manufacturer of superficial radiation therapy devices. The Company designs, manufactures and markets medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy. The superficial radiation therapy is an alternative to surgical basal cell carcinoma treatment and squamous cell carcinoma treatment. The Company’s product, the SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions, such as keloids. The SRT-100 treats primary lesions that would otherwise be difficult or require surgery involving sensitive areas of the head and neck regions, such as the fold in the nose, eyelids, lips, corner of the mouth and the lining of the ear.